A phase 0 clinical trial of novel candidate extended-release formulations of capecitabine.
Jacobs BA, Meulenaar J, Rosing H, Pluim D, Tibben MM, de Vries N, Nuijen B, Huitema AD, Beijnen JH, Schellens JH, Marchetti S.
Jacobs BA, et al.
Cancer Chemother Pharmacol. 2016 Jun;77(6):1201-7. doi: 10.1007/s00280-016-3035-5. Epub 2016 Apr 21.
Cancer Chemother Pharmacol. 2016.
PMID: 27103124
Clinical Trial.